Evidence map›Paper›PMID 40080642›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

RGMb drives macrophage infiltration to aggravate kidney disease.

Yonglun Kong, Ming Yue, Chunhua Xu, Jing Zhang, Huiling Hong, Jiahuan Lu, Yang Wang, Xiaoyi Zhang, Qiuju Chen, Chen Yang and 8 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. International journal of molecular sciences · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yonglun KongSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Ming YueAIDS Institute and Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.ORCID 0000-0002-4052-818X
Chunhua XuDepartment of Nephrology, Longgang Central Hospital of Shenzhen, Shenzhen 518116, China.
Jing ZhangSchool of Optometry, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.ORCID 0000-0001-7525-2075
Huiling HongSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Jiahuan LuSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Yang WangSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Xiaoyi ZhangSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Qiuju ChenSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0009-0000-5624-0175
Chen YangGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Affiliated Hospital, Guangdong Medical University, Zhanjiang 524023, China.
Hua-Feng LiuGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Affiliated Hospital, Guangdong Medical University, Zhanjiang 524023, China.
Jinzhong QinThe Key Laboratory of Model Animal for Disease Study of Ministry of Education, Model Animal Research Center, Nanjing University, Nanjing 210061, China.
Jingying ZhouSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Nam Y LeeDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724.
Bin LinSchool of Optometry, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.
Xiaoyu TianSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-3472-9898
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.ORCID 0000-0002-7210-5616
Yin XiaSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-0315-7532

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Health and Medical Research Fund (HMRF) 05161376 07180636 and 08190376HHS | National Institutes of Health (NIH) AI056299HHS | National Institutes of Health (NIH) P50CA101942MOST | National Natural Science Foundation of China (NSFC) 82400818NCI NIH HHS P50 CA101942NIAID NIH HHS P01 AI056299Research Grants Council, University Grants Committee () 14102620 14112121 14108922 and 14111523Shenzhen Longgang District Science and Technology Innovation Special Fund LGKCYLWS2024-5The Strategic Seed Funding for Collaborative Research Scheme, CUHK NL/SSFCRS2022/0674/22en
6 · The paper itself

Abstract

The importance of macrophages in kidney diseases has been well established; however, the mechanisms underlying the infiltration of macrophages into injured kidneys are not well understood. RGMb is a member of the repulsive guidance molecule (RGM) family. RGMb can be expressed on the cell surface but a large portion of RGMb is localized intracellularly. Among various immune cell types, macrophages express the highest levels of RGMb, but the biological functions of RGMb in macrophages remain largely unknown. We find that RGMb promoted macrophage migration in vitro and that in vivo, RGMb enhanced infiltration of macrophages into injured kidneys and aggravated kidney inflammation and injury in mice. Mechanistically, RGMb bound to TAB1 inside the cell and facilitated the interaction between TRAF6 ubiquitin ligase and TAB1, thereby promoting TRAF6-mediated K63-linked polyubiquitination and phosphorylation of TAK1, followed by increased αTAT1 phosphorylation and α-tubulin acetylation. The resulting changes in the cytoskeleton promoted macrophage migration in vitro and in vivo. Deletion of Rgmb in macrophages markedly reduced TAK1 phosphorylation, αTAT1 phosphorylation, and α-tubulin acetylation and attenuated macrophage infiltration, renal inflammation, tubular injury, and interstitial fibrosis during kidney injury. Our results suggest that macrophage RGMb promotes kidney disease by increasing macrophage infiltration via the TRAF6-TAB1-TAK1/αTAT1/α-tubulin cascade.

Indexed as

Cell Adhesion Molecules, NeuronalKidney DiseasesMacrophagesNerve Tissue ProteinsAdaptor Proteins, Signal TransducingAnimalsCell MovementHumansKidneyMaleMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMiceMice, Inbred C57BLPhosphorylationRAW 264.7 CellsAdaptor Proteins, Signal TransducingCell Adhesion Molecules, NeuronalMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesNerve Tissue ProteinsTNF Receptor-Associated Factor 6TRAF6 protein, mouseTubulinkidney diseasekidney inflammationmacrophage migrationRGMbTAB1

Identifiers

PMID40080642
PMCPMC11929492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.